FATEMEDIUM SIGNALFINANCIAL10-K

FATE shows mixed financial performance with significantly reduced revenue (-51.2%) but improved operational efficiency through lower losses and reduced R&D spending.

The company appears to be entering a transitional phase with substantially lower revenue but better cost management, as evidenced by reduced operating losses despite the revenue decline. The increased capital expenditures (+715.5%) alongside maintained cash position suggests strategic investments for future growth, though the dramatic decrease in stockholders' equity (-35%) indicates ongoing cash burn concerns.

Comparing 2026-02-26 vs 2025-03-05View on EDGAR →
FINANCIAL ANALYSIS

FATE's financials reflect a company in transition, with revenue declining sharply by 51.2% to $6.6M while the company simultaneously improved operational efficiency by reducing R&D expenses 20.1% and cutting operating losses by nearly 30%. Despite lower revenue, the company maintained a stronger cash position (+29.3% to $46.6M) while significantly increasing capital expenditures to $6.0M, suggesting strategic investments for future operations. However, the 35% decline in stockholders' equity to $207.2M and overall asset reduction of 27.6% highlight the ongoing cash consumption typical of a biotech company in development phase.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+715.5%
$730K→$6.0M

Capital expenditure jumped 715.5% — major investment cycle underway; assess returns on deployment.

Accounts Receivable
Balance Sheet
-74.1%
$3.5M→$916K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Revenue
P&L
-51.2%
$13.6M→$6.6M

Revenue declined 51.2% — significant demand weakness or market share loss warrants investigation.

Stockholders Equity
Balance Sheet
-35%
$318.7M→$207.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Income
P&L
+29.8%
-$210.3M→-$147.7M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Cash & Equivalents
Balance Sheet
+29.3%
$36.1M→$46.6M

Cash grew 29.3% — improving liquidity position supports investment and shareholder returns.

Current Assets
Balance Sheet
-28.5%
$291.9M→$208.7M

Current assets declined 28.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-27.6%
$440.7M→$318.9M

Total assets contracted 27.6% — asset sales, write-downs, or balance sheet optimization underway.

Net Income
P&L
+26.8%
-$186.3M→-$136.3M

Net income grew 26.8% — bottom-line growth signals improving overall business health.

R&D Expense
P&L
-20.1%
$135.0M→$107.8M

R&D spending cut 20.1% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-05
ADDED
The number of outstanding shares of the registrant s common stock, par value $0.001 per share, as of February 19, 2026 w as 116,263,459 .
Our product candidates and programs represent novel therapeutic approaches to treating disease, and our product candidates may fail to demonstrate the safety, potency, durability, and efficacy necessary to support further development or commercialization, or may cause undesirable side effects or have other properties that could delay or halt their preclinical or clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
We face significant competition in an environment of rapid technological change from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively, including with respect to the recruitment of patients and investigative sites to participate in our clinical trials.
Inadequate funding for the FDA, SEC, the National Institutes of Health and other government agencies, as well as changes in personnel and policy priorities at these agencies, could disrupt such agencies operations and, in turn, hinder our ability to develop or commercialize new products in a timely manner or otherwise negatively impact our business.
We depend on third-party suppliers, including sole source suppliers, for certain equipment and components used in the production of our product candidates, and the loss of suppliers could adversely impact our ability to conduct our clinical trials.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the registrant s common stock, par value $0.001 per share, as of February 25, 2025 w as 114,597,425 .
Our product candidates and programs represent novel therapeutic approaches to treating disease, and our product candidates may cause undesirable side effects or have other properties that could delay or halt their preclinical or clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
We face significant competition in an environment of rapid technological change from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
We depend on third-party suppliers, including sole source suppliers, for certain aspects in the production of our product candidates, the loss of which suppliers could adversely impact our ability to conduct our clinical trials.
Security breaches, loss of data and other disruptions could compromise sensitive information related to our business.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →